Should we listen to our clock to prevent type 2 diabetes mellitus?

Diabetes Research and Clinical Practice

Volumn 106, Issue 2, 2014, Pages 182-190

  Karthikeyan, Ramanujam ^a   Marimuthu, Ganapathy ^a   Spence, David Warren ^b   Pandi Perumal, Seithikurippu R ^c   BaHammam, Ahmed S ^d   Brown, Gregory M ^e   Cardinali, Daniel P ^f  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b Independent Researcher   (Canada)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e UNIVERSITY OF TORONTO   (Canada)

^f PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

Author keywords

Circadian rhythms; Clock genes; Melatonin; Metabolism; Type 2 diabetes mellitus

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; MELATONIN; METFORMIN;

CALORIC INTAKE; CIRCADIAN RHYTHM; DRUG EFFECT; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; LIGHT EXPOSURE; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHOTOTHERAPY; REVIEW; SLEEP WAKING CYCLE; SOCIAL PROBLEM; TRAVEL; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; METABOLISM; PATHOPHYSIOLOGY;

CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; HUMANS;

EID: 84920571752     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.07.029     Document Type: Review

References (95)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence in adults for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Res Clin Pract 2014, 103(2):137-149.
2. Zhang P., Zhang X., Brown J., Vistisen D., Sicree R., Shaw J., et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301.
3. Lin Y., Sun Z. Current views on type 2 diabetes. J Endocrinol 2010, 204:1-11.
4. Das S.K., Elbein S.C. The genetic basis of type 2 diabetes. Cell Sci 2006, 2:100-131.
5. Gangwisch J.E., Heymsfield S.B., Boden-Albala B., Buijs R.M., Kreier F., Pickering T.G., et al. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 2007, 30:1667-1673.
6. Maury E., Ramsey K.M., Bass J. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ Res 2010, 106:447-462.
7. Bennett P.H., Burch T.A., Miller M. Diabetes mellitus in American (pima) Indians. Lancet 1971, 2:125-128.
8. Zimmet P., Arblaster M., Thoma K. The effect of westernization on native populations. Studies on a Micronesian community with a high diabetes prevalence. Aust N Z J Med 1978, 8:141-146.
9. Bass J., Takahashi J.S. Circadian integration of metabolism and energetics. Science 2010, 330:1349-1354.
10. Shi S.Q., Ansari T.S., McGuinness O.P., Wasserman D.H., Johnson C.H. Circadian disruption leads to insulin resistance and obesity. Curr Biol 2013, 23:372-381.
11. Lamia K.A., Storch K.F., Weitz C.J. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci U S A 2008, 105:15172-15177.
12. Scheer F.A., Hilton M.F., Mantzoros C.S., Shea S.A. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 2009, 106:4453-4458.
13. Gale J.E., Cox H.I., Qian J., Block G.D., Colwell C.S., Matveyenko A.V. Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythms 2011, 26:423-433.
14. Arble D.M., Bass J., Laposky A.D., Vitaterna M.H., Turek F.W. Circadian timing of food intake contributes to weight gain. Obesity (Silver Spring) 2009, 17:2100-2102.
15. Ando H., Takamura T., Matsuzawa-Nagata N., Shima K.R., Eto T., Misu H., et al. Clock gene expression in peripheral leucocytes of patients with type 2 diabetes. Diabetologia 2009, 52:329-335.
16. Pappa K.I., Gazouli M., Anastasiou E., Iliodromiti Z., Antsaklis A., Anagnou N.P. Circadian clock gene expression is impaired in gestational diabetes mellitus. Gynecol Endocrinol 2013, 29:331-335.
17. Karthikeyan R., Marimuthu G., Sooriyakumar M., BaHammam A.S., Spence D.W., Pandi-Perumal S.R., et al. Per3 length polymorphism in patients with type 2 diabetes mellitus. Horm Mol Biol Clin Invest 2014, 18:145-149.
18. Kawakami N., Takatsuka N., Shimizu H. Sleep disturbance and onset of type 2 diabetes. Diabetes Care 2004, 27:282-283.
19. Knutson K.L., Spiegel K., Penev P., Van C.E. The metabolic consequences of sleep deprivation. Sleep Med Rev 2007, 11:163-178.
20. Wolk R., Somers V.K. Sleep and the metabolic syndrome. Exp Physiol 2007, 92:67-78.
21. Lyssenko V., Nagorny C.L., Erdos M.R., Wierup N., Jonsson A., Spegel P., et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009, 41:82-88.
22. Peschke E., Bahr I., Muhlbauer E. Melatonin and pancreatic islets interrelationships between melatonin, insulin and glucagon. Int J Mol Sci 2013, 14:6981-7015.
23. Mazzoccoli G., Pazienza V., Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol Int 2012, 29:227-251.
24. Hastings M.H., Brancaccio M., Maywood E.S. Circadian pacemaking in cells and circuits of the suprachiasmatic nucleus. J Neuroendocrinol 2014, 26:2-10.
25. Hirota T., Fukada Y. Resetting mechanism of central and peripheral circadian clocks in mammals. Zool Sci 2004, 21:359-368.
26. DeBruyne J.P., Weaver D.R., Reppert S.M. Peripheral circadian oscillators require CLOCK. Curr Biol 2007, 17:R538-R539.
27. Fonken L.K., Nelson R.J. The effects of light at night on circadian clocks and metabolism. Endocr Rev 2014, 35:648-670. er20131051.
28. Yang X., Downes M., Yu R.T., Bookout A.L., He W., Straume M., et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006, 126:801-810.
29. Buijs R.M., Scheer F.A., Kreier F., Yi C., Bos N., Goncharuk V.D., et al. Organization of circadian functions: interaction with the body. Prog Brain Res 2006, 153:341-360.
30. la Fleur S.E., Kalsbeek A., Wortel J., van d V., Buijs R.M. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night-time glucose concentrations. J Neuroendocrinol 2001, 13:1025-1032.
31. Coomans C.P., van den Berg S.A., Lucassen E.A., Houben T., Pronk A.C., van der Spek R.D., et al. The suprachiasmatic nucleus controls circadian energy metabolism and hepatic insulin sensitivity. Diabetes 2013, 62:1102-1108.
32. Turek F.W., Joshu C., Kohsaka A., Lin E., Ivanova G., McDearmon E., et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005, 308:1043-1045.
33. Rudic R.D., McNamara P., Curtis A.M., Boston R.C., Panda S., Hogenesch J.B., et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol 2004, 2:e377.
34. Yang S., Liu A., Weidenhammer A., Cooksey R.C., McClain D., Kim M.K., et al. The role of mPer2 clock gene in glucocorticoid and feeding rhythms. Endocrinology 2009, 150:2153-2160.
35. Marcheva B., Ramsey K.M., Buhr E.D., Kobayashi Y., Su H., Ko C.H., et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 2010, 466:627-631.
36. Shimba S., Ogawa T., Hitosugi S., Ichihashi Y., Nakadaira Y., Kobayashi M., et al. Deficient of a clock gene, brain and muscle Arnt-like protein-1 (BMAL1), induces dyslipidemia and ectopic fat formation. PLoS One 2011, 6:e25231.
37. Costa M.J., So A.Y., Kaasik K., Krueger K.C., Pillsbury M.L., Fu Y.H., et al. Circadian rhythm gene period 3 is an inhibitor of the adipocyte cell fate. J Biol Chem 2011, 286:9063-9070.
38. Bugge A., Feng D., Everett L.J., Briggs E.R., Mullican S.E., Wang F., et al. Rev-erbalpha and Rev-erbbeta coordinately protect the circadian clock and normal metabolic function. Genes Dev 2012, 26:657-667.
39. Cho H., Zhao X., Hatori M., Yu R.T., Barish G.D., Lam M.T., et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REV-ERB-beta. Nature 2012, 485:123-127.
40. Shimba S., Ishii N., Ohta Y., Ohno T., Watabe Y., Hayashi M., et al. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci U S A 2005, 102:12071-12076.
41. Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W., et al. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 2011, 480:552-556.
42. Dallmann R., Weaver D.R. Altered body mass regulation in male mPeriod mutant mice on high-fat diet. Chronobiol Int 2010, 27:1317-1328.
43. So A.Y.L., Bernal T.U., Pillsbury M.L., Yamamoto K.R., Feldman B.J. Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. Proc Natl Acad Sci U S A 2009, 106:17582-17587.
44. Scheen A.J., Byrne M.M., Plat L., Leproult R., Van C.E. Relationships between sleep quality and glucose regulation in normal humans. Am J Physiol 1996, 271:E261-E270.
45. Ramsey K.M., Bass J. Obeying the clock yields benefits for metabolism. Proc Natl Acad Sci U S A 2009, 106:4069-4070.
46. Stokkan K.A., Yamazaki S., Tei H., Sakaki Y., Menaker M. Entrainment of the circadian clock in the liver by feeding. Science 2001, 291:490-493.
47. Feillet C.A. Food for thoughts: feeding time and hormonal secretion. J Neuroendocrinol 2010, 22:620-628.
48. Wu T., ZhuGe F., Sun L., Ni Y., Fu O., Gao G., et al. Enhanced effect of daytime restricted feeding on the circadian rhythm of streptozotocin-induced type 2 diabetic rats. Am J Physiol Endocrinol Metab 2012, 302:E1027-E1035.
49. Kohsaka A., Laposky A.D., Ramsey K.M., Estrada C., Joshu C., Kobayashi Y., et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab 2007, 6:414-421.
50. Hatori M., Vollmers C., Zarrinpar A., DiTacchio L., Bushong E.A., Gill S., et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 2012, 15:848-860.
51. Fonken L.K., Workman J.L., Walton J.C., Weil Z.M., Morris J.S., Haim A., et al. Light at night increases body mass by shifting the time of food intake. Proc Natl Acad Sci U S A 2010, 107:18664-18669.
52. Cardinali D.P., Cano P., Jimenez-Ortega V., Esquifino A.I. Melatonin and the metabolic syndrome. Physiopathologic and therapeutical implications. Neuroendocrinology 2011, 93:133-142.
53. Lazar M.A. How obesity causes diabetes: not a tall tale. Science 2005, 307:373-375.
54. Polonsky K.S. The past 200 years in diabetes. N Engl J Med 2012, 367:1332-1340.
55. Kelly M.A., Rees S.D., Hydrie M.Z., Shera A.S., Bellary S., O'Hare J.P., et al. Circadian gene variants and susceptibility to type 2 diabetes: a pilot study. PLoS One 2012, 7:e32670.
56. Woon P.Y., Kaisaki P.J., Braganca J., Bihoreau M.T., Levy J.C., Farrall M., et al. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci U S A 2007, 104:14412-14417.
57. Sookoian S., Gemma C., Gianotti T.F., Burgueno A., Castano G., Pirola C.J. Genetic variants of Clock transcription factor are associated with individual susceptibility to obesity. Am J Clin Nutr 2008, 87:1606-1615.
58. Scott E.M., Carter A.M., Grant P.J. Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man. Int J Obes (Lond) 2008, 32:658-662.
59. Monteleone P., Tortorella A., Docimo L., Maldonato M.N., Canestrelli B., De L.L., et al. Investigation of 3111T/C polymorphism of the CLOCK gene in obese individuals with or without binge eating disorder: association with higher body mass index. Neurosci Lett 2008, 435:30-33.
60. Garaulet M., Corbalan M.D., Madrid J.A., Morales E., Baraza J.C., Lee Y.C., et al. CLOCK gene is implicated in weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. Int J Obes (Lond) 2010, 34:516-523.
61. Bostwick J., Nguyen D., Cornelissen G., Halberg F., Hoogerwerf W.A. Effects of acute and chronic STZ-induced diabetes on clock gene expression and feeding in the gastrointestinal tract. Mol Cell Biochem 2010, 338:203-213.
62. Wu T., ZhuGe F., Zhu Y., Wang N., Jiang Q., Fu H., et al. Effects of light on the circadian rhythm of diabetic rats under restricted feeding. J Physiol Biochem 2014, 70:61-71.
63. Stamenkovic J.A., Olsson A.H., Nagorny C.L., Malmgren S., kker-Nitert M., Ling C., et al. Regulation of core clock genes in human islets. Metabolism 2012, 61:978-985.
64. Hirota T., Okano T., Kokame K., Shirotani-Ikejima H., Miyata T., Fukada Y. Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts. J Biol Chem 2002, 277:44244-44251.
65. Pandi-Perumal S.R., Srinivasan V., Maestroni G.J.M., Cardinali D.P., Poeggeler B., Hardeland R. Melatonin Nature's most versatile biological signal?. FEBS J 2006, 273:2813-2838.
66. Reiter R.J., Rosales-Corral S., Coto-Montes A., Boga J.A., Tan D.X., Davis J.M., et al. The photoperiod, circadian regulation and chronodisruption: the requisite interplay between the suprachiasmatic nuclei and the pineal and gut melatonin. J Physiol Pharmacol 2011, 62:269-274.
67. Gooley J.J., Chamberlain K., Smith K.A., Khalsa S.B., Rajaratnam S.M., Van R.E., et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab 2011, 96:E463-E472.
68. Reiter R.J., Tan D.X., Korkmaz A., Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med 2012, 44:564-577.
69. Boden G., Ruiz J., Urbain J.L., Chen X. Evidence for a circadian rhythm of insulin secretion. Am J Physiol 1996, 271:E246-E252.
70. Boden G., Chen X., Urbain J.L. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996, 45:1044-1050.
71. Peschke E., Peschke D., Hammer T., Csernus V. Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro. J Pineal Res 1997, 23:156-163.
72. Tutuncu N.B., Batur M.K., Yildirir A., Tutuncu T., Deger A., Koray Z., et al. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res 2005, 39:43-49.
73. Bouatia-Naji N., Bonnefond A., Cavalcanti-Proenca C., Sparso T., Holmkvist J., Marchand M., et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009, 41:89-94.
74. Bonnefond A., Clement N., Fawcett K., Yengo L., Vaillant E., Guillaume J.L., et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012, 44:297-301.
75. Waldhauser F., Vierhapper H., Pirich K. Abnormal circadian melatonin secretion in night-shift workers. N Engl J Med 1986, 315:1614.
76. Sack R.L., Blood M.L., Lewy A.J. Melatonin rhythms in night shift workers. Sleep 1992, 15:434-441.
77. Um J.H., Yang S., Yamazaki S., Kang H., Viollet B., Foretz M., et al. Activation of 5'-AMP-activated kinase with diabetes drug metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J Biol Chem 2007, 282:20794-20798.
78. Lefterova M.I., Zhang Y., Steger D.J., Schupp M., Schug J., Cristancho A., et al. PPAR gamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev 2008, 22:2941-2952.
79. Marcheva B., Ramsey K.M., Bass J. Circadian genes and insulin exocytosis. Cell Logist 2011, 1:32-36.
80. Garaulet M., Madrid J.A. Chronobiology, genetics and metabolic syndrome. Curr Opin Lipidol 2009, 20:127-134.
81. Szosland D. Shift work and metabolic syndrome, diabetes mellitus and ischaemic heart disease. Int J Occup Med Environ Health 2010, 23:287-291.
82. Cailotto C., Lei J., van d V., Van H.C., van Eden C.G., Kalsbeek A., et al. Effects of nocturnal light on (clock) gene expression in peripheral organs: a role for the autonomic innervation of the liver. PLoS One 2009, 4:e5650.
83. Arendt J., Skene D.J. Melatonin as a chronobiotic. Sleep Med Rev 2005, 9:25-39.
84. Cardinali D.P., Furio A.M., Reyes M.P. Clinical perspectives for the use of melatonin as a chronobiotic-cytoprotective agent. Ann NY Acad Sci 2005, 1057:327-336.
85. Touitou Y., Bogdan A. Promoting adjustment of the sleep-wake cycle by chronobiotics. Physiol Behav 2007, 90:294-300.
86. Cardinali D.P., Pagano E.S., Scacchi P.A., Reynoso R., Scacchi P. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. Neuroendocrinol Lett 2011, 32:588-606.
87. Tan D.X., Manchester L.C., Fuentes-Broto L., Paredes S.D., Reiter R.J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011, 12:167-188.
88. Kozirog M., Poliwczak A.R., Duchnowicz P., Koter-Michalak M., Sikora J., Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011, 50:261-266.
89. Gonciarz M., Bielanski W., Partyka R., Brzozowski T., Konturek P.C., Eszyk J., et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. J Pineal Res 2013, 54:154-161.
90. Gonciarz M., Gonciarz Z., Bielanski W., Mularczyk A., Konturek P.C., Brzozowski T., et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012, 63:35-40.
91. Gonciarz M., Gonciarz Z., Bielanski W., Mularczyk A., Konturek P.C., Brzozowski T., et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol 2010, 61:705-710.
92. Romo-Nava F., Alvarez-Icaza G.D., Fresan-Orellana A., Saracco A.R., Becerra-Palars C., Moreno J., et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord 2014, 16:410-421.
93. Modabbernia A., Heidari P., Soleimani R., Sobhani A., Roshan Z.A., Taslimi S., et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res 2014, 53:133-140.
94. Cardinali D.P., Srinivasan V., Brzezinski A., Brown G.M. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012, 52:365-375.
95. Weishaupt J.H., Bartels C., Polking E., Dietrich J., Rohde G., Poeggeler B., et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006, 41:313-323.